EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Biogen Inc. (0R1B) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Biogen Inc. $252, price $220, upside +14.6%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Health Care · GB · Home US

BI Some data Sep 29, 2026

Biogen Inc.

0R1B · LSE

UndervaluedQuality growthThe stock appears undervalued with acceptable quality.

✓Fair value $252.15 · Undervalued (+14.6%)
✓Quality 67/100
!Weak Growth (revenue 5y −5.1 %/yr)
!Thin margins · 8.3% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (11/12)
!Moderate moat 52/100
!Evidence only medium, so the estimate is less certain
!Weak on future: 17 out of 100
!Weak on past: 18 out of 100
Watch Biogen Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$390.13 $114.30 Fair Value $252.15 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range $114.30 – $390.13 · fair‑value band $173.88 – $334.80 · the $220.13 price screens below the $252.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 29, 2026.

Follow Biogen in your weekly email

Every Wednesday you see whether Biogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Show more

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Biogen Inc. (0R1B) currently trades at $220.13, while our model-based Fair Value estimate is $252.15, implying the stock looks roughly 12.7% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $287.34 per share, and 13 of the 24 models we run sit above the $220.13 price.

Bear case: the Asset-Based group reads lowest at $82.75, and 11 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $173.88 (bear) to $334.80 (bull), the price of $220.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Health Care sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Biogen Inc. reported revenue of $9.5B in FY2025 versus $10.4B in FY2021, a compound −2.2%/yr. Reported net income was $1.3B in FY2025, compounding −4.5%/yr from FY2021.

Key figures

Market cap $32.4B · P/S ratio 3.25 · Net margin 13.6% · Return on equity 4.6% · Return on assets (EBIT) 8.7% · Operating margin 25.1% · Revenue (TTM) $10.0B · Revenue growth (YoY) +3.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 4% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Health Care peers we cover trades at 10% fair-value upside, at 15%, 0R1B screens cheaper than that median.

Fair Value models

Bear $173.88 Fair Value $252.15 Bull $334.80
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $196.81 $388.27 $841.55 74
EPV $124.85 $149.33 $170.76 74
Growth DCF $191.31 $407.07 $745.18 74
All 24 models by family
DCF Models
FCF DCF $196.81 $388.27 $841.55 74
Owner Earnings $184.21 $393.56 $791.86 71
5Y Revenue Exit $140.03 $271.19 $455.04 70
5Y EBITDA Exit $200.27 $403.86 $672.19 72
5Y P/E Exit $139.51 $270.04 $425.86 69
10Y Revenue Exit $151.72 $287.34 $509.75 64
10Y EBITDA Exit $197.82 $388.38 $703.79 65
10Y P/E Exit $156.40 $286.46 $483.67 62
Earnings-Based
Graham-Dodd $59.47 $340.53 $473.49 63
Lynch FV $95.87 $136.96 $178.05 61
PEG = 1.0 $95.87 $136.96 $178.05 57
EPV $124.85 $149.33 $170.76 74
Multiples
P/E Multiple $144.31 $192.41 $240.52 63
P/S Multiple $111.51 $148.68 $185.85 58
P/B Multiple $111.51 $148.68 $185.85 55
EV/EBIT $197.35 $270.50 $343.65 66
EV/EBITDA $214.02 $292.73 $371.43 67
EV/Revenue $113.34 $171.37 $229.41 53
Asset-Based
NCAV (Graham) $61.75 $82.75 $123.50 54
Growth DCF
Growth DCF $191.31 $407.07 $745.18 74
Rev-Margin DCF $140.03 $266.93 $442.79 70
Economic Profit
Residual Income $100.33 $105.71 $116.92 71
ROIC Compounder $125.89 $187.38 $246.38 71
Growth Earnings
Growth-Adj P/E $145.53 $207.90 $270.27 67

Open the full fair value analysis →

Notify me when 0R1B reaches fair value

Put 0R1B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 66 · Market factors (momentum, volatility) 81

Profitability 38
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 87
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 72
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 73
Price trend over the last 3–12 months (market factor)
52W Momentum 95
Distance to the 52-week high (market factor)
Net Issuance 76
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Start year 2020 (pandemic). Over 10 years: +0.2% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−18.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−18.7% vs −5.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 27%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.7% a year for the price and +0.9% for the forecasts.
Forecast 2026 (sales)+9.4%
Forecast 2027 (sales)+1.9%
Projected 2028 (sales)+1.9%
Projected 2029 (sales)+1.9%
Projected 2030 (sales)+1.9%

Watch 0R1B, get fair value alerts →

Compare Biogen Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 67 · Top 25%
Fair Value upside +14.5% · Top 25%
Profitability
Return on equity (TTM) 4.6% · Above median
Return on assets 5.2% · Top 25%
Net margin (TTM) 8.3% · Above median
Operating margin (TTM) 25.1% · Top 25%
Growth and dividend
Revenue growth 3.4% · Above median
Balance sheet
Debt / equity 0.34× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.77× · Cheaper than median
P/S (TTM) 3.23× · Cheaper than median
P/FCF 15.8× · Cheaper than median
EV/EBITDA 10.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)53 · sector 0
FUTURE (revenue growth)17 · sector 0
PAST (return on equity)18 · sector 0
HEALTH (low debt)83 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biogen Inc. · Fair Value
$252.15 +13%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Biogen Inc. Fair Value". https://www.fairvalue-calculator.com/stock/0R1B

Frequently asked questions

Is Biogen Inc. (0R1B) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $252.15 versus a price of $220.13, about +15% upside (undervalued).
What is the fair value of 0R1B?
Our model-based fair value for Biogen Inc. is $252.15 (as of Sep 29, 2026), built from audited fundamentals. The current price: $220.13.
What is the quality score of 0R1B?
Biogen Inc. has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biogen Inc. (0R1B)?
Our model-based price target is the fair value of $252.15 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario $173.88, optimistic scenario $334.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Biogen Inc. stock forecast for 2026?
Our models put fair value at $252.15, about +15% upside versus a price of $220.13 (undervalued). Cautious scenario $173.88, optimistic scenario $334.80. The calculation is refreshed regularly with new filings.
What is the revenue of Biogen Inc. (0R1B)?
Biogen Inc. reported trailing-twelve-month revenue of about $10.0B (latest available figure, as of Sep 29, 2026).
What growth is priced into Biogen Inc. (0R1B)?
For today's price to be fair in a discounted-cash-flow model, Biogen Inc. would have to grow free cash flow by +8.2 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.1 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of 0R1B use?
Our models discount Biogen Inc. at 8.6 %: a base by market capitalisation (large), damped by beta 0.16, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biogen Inc. that is +8.2 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Biogen Inc. (0R1B) delivered so far?
Over the past 5 years revenue at Biogen Inc. grew -5.1 % a year. The price currently implies +8.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Biogen Inc. (0R1B)?
The free-cash-flow yield on the price is 4.78 %: that much free cash flow Biogen Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biogen Inc. (0R1B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biogen Inc. it is $252.15 per share (as of Sep 29, 2026), against a price of $220.13. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Biogen Inc. stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0R1B trades below its calculated fair value: price $220.13, fair value $252.15, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0R1B?
No. The price is what the market pays today ($220.13); the fair value is what the company's own numbers justify ($252.15). For Biogen Inc. the two are $32.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biogen Inc. worth?
The market values Biogen Inc. at about $32.4B (market capitalisation, as of Sep 29, 2026). Per share that is $220.13; our models calculate a fair value of $252.15 per share.
What do the bullish and bearish scenarios say about 0R1B?
Our models span a range for Biogen Inc.: cautious scenario $173.88, base $252.15, optimistic $334.80 per share (as of Sep 29, 2026, price $220.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biogen Inc. (0R1B)?
Balance-sheet figures for Biogen Inc. (as of Sep 29, 2026): return on equity 4.6%, debt of 0.34 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 0R1B from its 52-week high?
Biogen Inc. trades at $220.13, about 4% below its 52-week high of $228.41 and 55% above the low of $142.43 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $252.15 is for.
Which stocks are comparable to Biogen Inc.?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biogen Inc. stock attractive at the current price?
The data as of Sep 29, 2026: price $220.13, calculated fair value $252.15 (+15%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0R1B calculated?
We run Biogen Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $252.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Biogen Inc. currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biogen Inc. (0R1B)?
The closing price on Oct 2, 2026 was $220.13. Our model-based fair value is $252.15, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biogen Inc. right now?
A fairly wide model range ($173.88 to $334.80) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Biogen Inc. (0R1B) come from?
Earnings per share at Biogen Inc. grew −5.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin −6.6 %, tax rate +1.5 %, residual (interest, one-offs) −4.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Biogen Inc.

How large is the market capitalisation of Biogen Inc. (0R1B)?
The market capitalisation of Biogen Inc. is $32.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biogen Inc. (0R1B)?
The price-to-sales ratio of Biogen Inc. is 3.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Biogen Inc. (0R1B)?
The net margin of Biogen Inc. is 13.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biogen Inc. (0R1B)?
The return on equity (ROE) of Biogen Inc. is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biogen Inc. (0R1B)?
On an EBIT basis the return on assets of Biogen Inc. is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biogen Inc. (0R1B)?
The operating margin of Biogen Inc. is 25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biogen Inc. (0R1B)?
Revenue at Biogen Inc. is growing +3.4% versus a year earlier (3y avg +0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biogen Inc. (0R1B)?
Earnings per share at Biogen Inc. are growing −84.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Biogen Inc. (0R1B) carry?
The net debt of Biogen Inc. is $3.9B (fiscal year 2025, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biogen Inc. in the live analysis

One click puts Biogen Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.